Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba TrialAnne Sophie Kubasch, Uwe Platzbecker, Martin Puttrich et al.|Blood|2018Cited by 17
Designing a single-arm phase 2 clinical trial of mitapivat for adult patients with erythrocyte membranopathies (SATISFY): a framework for interventional trials in rare anaemias – pilot study protocolAndreas Glenthøj, Kevin H.M. Kuo, Eduard J. van Beers et al.|BMJ Open|2024Cited by 11
Satisfy: A Eurobloodnet Multicenter, Single-Arm Phase 2 Trial of Mitapivat in Adult Patients with Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II - Results from the 8-Week Dose-Escalation PeriodThomas Doeven, Andreas Glenthøj, Eduard J. van Beers et al.|Blood|2024Cited by 2
Safety and Efficacy of Mitapivat in Adult Patients with Erythrocyte Membranopathies (SATISFY)Andreas Glenthoej, Kevin H.M. Kuo, Eduard J. van Beers et al.|Blood|2023Cited by 1